Angiogenesis is the mechanism of blood vessel formation after the first few days of embryogenesis, and is essential for all tissue growth. In adults, angiogenesis occurs in the thyroid during disease processes including goitre, Graves' disease, thyroiditis and cancer. The molecular mechanisms controlling angiogenesis are becoming clearer, and therapy targeting these processes is coming closer to clinical fruition. Both promoters and inhibitors of angiogenesis have been identified in the thyroid, including vascular endothelial growth factor (VEGF), fibroblast growth factor, and thrombospondin. This commentary will review the understanding of the control of angiogenesis within the context of the thyroid gland, and review the pre-eminent role of VEGF as the angiogenic signal from the follicular cells to the endothelial cells.

This article has been cited by other articles:

				S. M. Wiseman, A. Melck, H. Masoudi, F. Ghaidi, L. Goldstein, A. Gown, S. J. M. Jones, and O. L. Griffith Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis Ann. Surg. Oncol., October 1, 2008; 15(10): 2811 - 2826. [Abstract] [Full Text] [PDF]

				A.-C. Gerard, S. Poncin, B. Caetano, P. Sonveaux, J.-N. Audinot, O. Feron, I. M. Colin, and F. Soncin Iodine Deficiency Induces a Thyroid Stimulating Hormone-Independent Early Phase of Microvascular Reshaping in the Thyroid Am. J. Pathol., March 1, 2008; 172(3): 748 - 760. [Abstract] [Full Text] [PDF]

				I. Tamaskar, R. Bukowski, P. Elson, A. G. Ioachimescu, L. Wood, R. Dreicer, T. Mekhail, J. Garcia, and B. I. Rini Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib Ann. Onc., February 1, 2008; 19(2): 265 - 268. [Abstract] [Full Text] [PDF]

				J. Klubo-Gwiezdzinska, R. Junik, E. Kopczynska, O. Juraniec, and H. Kardymowicz The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter Eur. J. Endocrinol., October 1, 2007; 157(4): 521 - 527. [Abstract] [Full Text] [PDF]

				Y. Erbil, Y. Ozluk, M. Giris, A. Salmaslioglu, H. Issever, U. Barbaros, Y. Kapran, S. Ozarmagan, and S. Tezelman Effect of Lugol Solution on Thyroid Gland Blood Flow and Microvessel Density in the Patients with Graves' Disease J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2182 - 2189. [Abstract] [Full Text] [PDF]

				M. P. Foschini, M. Ragazzi, A. L. Parmeggiani, A. Righi, F. Flamminio, D. Meringolo, and L. Castaldini Comparison Between Echo-Color Doppler Sonography Features and Angioarchitecture of Thyroid Nodules International Journal of Surgical Pathology, April 1, 2007; 15(2): 135 - 142. [Abstract] [PDF]

				B. I. Rini, I. Tamaskar, P. Shaheen, R. Salas, J. Garcia, L. Wood, S. Reddy, R. Dreicer, and R. M. Bukowski Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib J Natl Cancer Inst, January 3, 2007; 99(1): 81 - 83. [Abstract] [Full Text] [PDF]

				M. N. Younes, Y. D. Yazici, S. Kim, S. A. Jasser, A. K. El-Naggar, and J. N. Myers Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3425 - 3434. [Abstract] [Full Text] [PDF]

				Y. Denizot, T. Chianea, F. Labrousse, V. Truffinet, M. Delage, and M. Mathonnet Platelet-activating factor and human thyroid cancer Eur. J. Endocrinol., July 1, 2005; 153(1): 31 - 40. [Abstract] [Full Text] [PDF]

				M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al. Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation Cancer Res., June 1, 2005; 65(11): 4716 - 4727. [Abstract] [Full Text] [PDF]

				F. Sorvillo, G. Mazziotti, A. Carbone, M. Piscopo, M. Rotondi, M. Cioffi, P. Musto, B. Biondi, S. Iorio, G. Amato, et al. Recombinant Human Thyrotropin Reduces Serum Vascular Endothelial Growth Factor Levels in Patients Monitored for Thyroid Carcinoma Even in the Absence of Thyroid Tissue J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4818 - 4822. [Abstract] [Full Text] [PDF]

				A. J. Bauer, A. Patel, R. Terrell, K. Doniparthi, M. Saji, M. Ringel, R. M. Tuttle, and G. L. Francis Systemic Administration of Vascular Endothelial Growth Factor Monoclonal Antibody Reduces the Growth of Papillary Thyroid Carcinoma in a Nude Mouse Model Ann. Clin. Lab. Sci., April 1, 2003; 33(2): 192 - 199. [Abstract] [Full Text] [PDF]

				R. M. Tuttle, M. Fleisher, G. L. Francis, and R. J. Robbins Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1737 - 1742. [Abstract] [Full Text] [PDF]